GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using our novel Modified Vaccinia Ankara (MVA) Virus-Like Particle (VLP) platform technology.
Our proprietary vaccine technology has been developed through multi-year collaborations with the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC), and Emory University. Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.
Our current development programs are focused on vaccines against Human Immunodeficiency Virus (HIV), Hemorrhagic Fever viruses (Ebola, Sudan, Marburg and Lassa) and Zika virus. We also have initiated programs to develop a vaccine to treat chronic Hepatitis B infection and to apply our MVA-VLP vector technology to cancer immunotherapy (immuno-oncology). We believe our technology and vaccine development expertise is well-suited for a wide variety of human diseases and we intend to pursue expansion of our product.
We know our work could affect the lives of millions worldwide, and we invite you to join our effort.
Robert McNally, CEO of GeoVax Labs Inc.,
Watch This Informative 3 Minute Clip Presented By GeoVax President and CEO Robert McNally Giving An Overview Of The Company
GOVX Zika Quicklinks:
October, 2016 GeoVax to Present at Upcoming Scientific Conferences on its Hemorrhagic Fever and Zika Vaccine Programs
June, 2016 GeoVax Discusses Zika Vaccine Development at American Society for Virology’s 35th Annual Meeting
June, 2016 GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting
May, 2016 GeoVax Presents at Zika Virus Scientific Conference
April, 2016 GeoVax Provides Update on Zika Vaccine Program
March, 2016 GeoVax Extends Research Collaborations on Zika Vaccine
March, 2016 GeoVax Applauds Passage of Senate Bill to Accelerate Development of Zika Virus Vaccines
February, 2016 GeoVax to Develop Vaccine Against Zika Virus
Long Speculation on GOVX's Zika Vaccine: On November 6, 2016, 60 Minutes did a segment titled: The Zika Virus
. The pieced highlighted a Zika vaccine platform that appears to be proving successful. The platform described is similar to that of GOVX' s Intellectual Property
. Other connections include a CDC sponsorship & Emory University. No definitive evidence has been disclosed.